- Home
- SANG vs INBX Comparison
SANG vs INBX Comparison
Compare SANG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- INBX
- Stock Information
- Founded
- SANG 1984
- INBX 2010
- Country
- SANG Canada
- INBX United States
- Employees
- SANG N/A
- INBX N/A
- Industry
- SANG Computer Software: Programming Data Processing
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- INBX Health Care
- Exchange
- SANG Nasdaq
- INBX Nasdaq
- Market Cap
- SANG 193.2M
- INBX 218.9M
- IPO Year
- SANG 2021
- INBX 2020
- Fundamental
- Price
- SANG $6.68
- INBX $14.86
- Analyst Decision
- SANG
- INBX Hold
- Analyst Count
- SANG 0
- INBX 1
- Target Price
- SANG N/A
- INBX N/A
- AVG Volume (30 Days)
- SANG 7.8K
- INBX 71.2K
- Earning Date
- SANG 02-06-2025
- INBX 11-14-2024
- Dividend Yield
- SANG N/A
- INBX N/A
- EPS Growth
- SANG N/A
- INBX N/A
- EPS
- SANG N/A
- INBX 119.38
- Revenue
- SANG $244,406,000.00
- INBX $1,568,000.00
- Revenue This Year
- SANG $3.36
- INBX N/A
- Revenue Next Year
- SANG $7.39
- INBX N/A
- P/E Ratio
- SANG N/A
- INBX $0.12
- Revenue Growth
- SANG N/A
- INBX 19.24
- 52 Week Low
- SANG $2.50
- INBX $10.80
- 52 Week High
- SANG $6.93
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SANG 56.18
- INBX 52.04
- Support Level
- SANG $6.45
- INBX $14.19
- Resistance Level
- SANG $6.93
- INBX $15.22
- Average True Range (ATR)
- SANG 0.22
- INBX 0.66
- MACD
- SANG 0.03
- INBX 0.00
- Stochastic Oscillator
- SANG 72.22
- INBX 49.13
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.